You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

IPCA Lab slumps after USFDA bans drugs from three plants

Capital Market 

fell 11.87% to Rs 452.25 at 9:28 on after the company said its facilities at Indore, Silvassa and have been banned from the US market.

The announcement was made after market hours yesterday, 15 June 2017.

Meanwhile, the S&P Sensex was up 62.99 points, or 0.20% to 31,138.72.

On the BSE, 2.03 lakh shares were traded in the counter so far, compared with average daily volumes of 17,332 shares in the past one quarter. The stock had hit a high of Rs 468 and a low of Rs 437 so far during the day. The stock hit a 52-week high of Rs 656 on 5 April 2017. The stock hit a 52-week low of Rs 435 on 24 June 2016.

The stock had underperformed the market over the past one month till 15 June 2017, falling 5.75% compared with 1.36% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 6.55% as against Sensex's 4.81% rise. The scrip had also underperformed the market in past one year, rising 6.95% as against Sensex's 17.15% rise.

The mid-cap company has equity capital of Rs 25.24 crore. Face value per share is Rs 2.

said that drugs manufactured at its facilities at SEZ Indore (Pithampur), Piparia (Silvassa) and Ratlam (Madhya Pradesh) have been banned from the US market by the US Food and Drug Administration (USFDA). The drug regulator cited violation of current good manufacturing norms for taking the step against the company. The USFDA has refused admission to all drugs made at the company's Pithampur and Silvassa facility. All drugs, except API Chloroquine Phosphate, made at Ratlam (Madhya Pradesh) unit have also been denied entry in the US, it further said. The ban will continue until the company can demonstrate that the drugs manufactured from these manufacturing sites and intended for the US market are in compliance with the current good manufacturing practice regulation (cGMP).

Net profit of rose 34.8% to Rs 44.39 on 6% rise in net sales to Rs 665.80 crore in Q4 March 2017 over Q4 March 2016.

is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 Active Pharmaceutical Ingredients (APIs) for various therapeutic segments.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

IPCA Lab slumps after USFDA bans drugs from three plants

IPCA Laboratories fell 11.87% to Rs 452.25 at 9:28 IST on BSE after the company said its facilities at Indore, Silvassa and Madhya Pradesh have been banned from the US market.

fell 11.87% to Rs 452.25 at 9:28 on after the company said its facilities at Indore, Silvassa and have been banned from the US market.

The announcement was made after market hours yesterday, 15 June 2017.

Meanwhile, the S&P Sensex was up 62.99 points, or 0.20% to 31,138.72.

On the BSE, 2.03 lakh shares were traded in the counter so far, compared with average daily volumes of 17,332 shares in the past one quarter. The stock had hit a high of Rs 468 and a low of Rs 437 so far during the day. The stock hit a 52-week high of Rs 656 on 5 April 2017. The stock hit a 52-week low of Rs 435 on 24 June 2016.

The stock had underperformed the market over the past one month till 15 June 2017, falling 5.75% compared with 1.36% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 6.55% as against Sensex's 4.81% rise. The scrip had also underperformed the market in past one year, rising 6.95% as against Sensex's 17.15% rise.

The mid-cap company has equity capital of Rs 25.24 crore. Face value per share is Rs 2.

said that drugs manufactured at its facilities at SEZ Indore (Pithampur), Piparia (Silvassa) and Ratlam (Madhya Pradesh) have been banned from the US market by the US Food and Drug Administration (USFDA). The drug regulator cited violation of current good manufacturing norms for taking the step against the company. The USFDA has refused admission to all drugs made at the company's Pithampur and Silvassa facility. All drugs, except API Chloroquine Phosphate, made at Ratlam (Madhya Pradesh) unit have also been denied entry in the US, it further said. The ban will continue until the company can demonstrate that the drugs manufactured from these manufacturing sites and intended for the US market are in compliance with the current good manufacturing practice regulation (cGMP).

Net profit of rose 34.8% to Rs 44.39 on 6% rise in net sales to Rs 665.80 crore in Q4 March 2017 over Q4 March 2016.

is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 Active Pharmaceutical Ingredients (APIs) for various therapeutic segments.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

IPCA Lab slumps after USFDA bans drugs from three plants

fell 11.87% to Rs 452.25 at 9:28 on after the company said its facilities at Indore, Silvassa and have been banned from the US market.

The announcement was made after market hours yesterday, 15 June 2017.

Meanwhile, the S&P Sensex was up 62.99 points, or 0.20% to 31,138.72.

On the BSE, 2.03 lakh shares were traded in the counter so far, compared with average daily volumes of 17,332 shares in the past one quarter. The stock had hit a high of Rs 468 and a low of Rs 437 so far during the day. The stock hit a 52-week high of Rs 656 on 5 April 2017. The stock hit a 52-week low of Rs 435 on 24 June 2016.

The stock had underperformed the market over the past one month till 15 June 2017, falling 5.75% compared with 1.36% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 6.55% as against Sensex's 4.81% rise. The scrip had also underperformed the market in past one year, rising 6.95% as against Sensex's 17.15% rise.

The mid-cap company has equity capital of Rs 25.24 crore. Face value per share is Rs 2.

said that drugs manufactured at its facilities at SEZ Indore (Pithampur), Piparia (Silvassa) and Ratlam (Madhya Pradesh) have been banned from the US market by the US Food and Drug Administration (USFDA). The drug regulator cited violation of current good manufacturing norms for taking the step against the company. The USFDA has refused admission to all drugs made at the company's Pithampur and Silvassa facility. All drugs, except API Chloroquine Phosphate, made at Ratlam (Madhya Pradesh) unit have also been denied entry in the US, it further said. The ban will continue until the company can demonstrate that the drugs manufactured from these manufacturing sites and intended for the US market are in compliance with the current good manufacturing practice regulation (cGMP).

Net profit of rose 34.8% to Rs 44.39 on 6% rise in net sales to Rs 665.80 crore in Q4 March 2017 over Q4 March 2016.

is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 Active Pharmaceutical Ingredients (APIs) for various therapeutic segments.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22